Wells Fargo’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-10
| Closed | -$89 | – | 7657 |
|
|
2024
Q1 | $89 | Hold |
10
| – | – | ﹤0.01% | 6693 |
|
|
2023
Q4 | $36 | Buy |
10
+1
| +11% | +$4 | ﹤0.01% | 7025 |
|
|
2023
Q3 | $31 | Buy |
9
+1
| +13% | +$5 | ﹤0.01% | 7057 |
|
|
2023
Q2 | $47 | Sell |
8
-3
| -27% | -$55 | ﹤0.01% | 7073 |
|
|
2023
Q1 | $423 | Hold |
11
| – | – | ﹤0.01% | 6598 |
|
|
2022
Q4 | $323 | Sell |
11
-35
| -76% | -$1.06K | ﹤0.01% | 6495 |
|
|
2022
Q3 | $1K | Hold |
46
| – | – | ﹤0.01% | 6510 |
|
|
2022
Q2 | $2K | Buy |
46
+1
| +2% | +$39 | ﹤0.01% | 6403 |
|
|
2022
Q1 | $2K | Sell |
45
-22
| -33% | -$1.11K | ﹤0.01% | 6714 |
|
|
2021
Q4 | $3K | Hold |
67
| – | – | ﹤0.01% | 6836 |
|
|
2021
Q3 | $5K | Sell |
67
-371
| -85% | -$31.4K | ﹤0.01% | 6396 |
|
|
2021
Q2 | $57K | Buy |
438
+187
| +75% | +$25.9K | ﹤0.01% | 5506 |
|
|
2021
Q1 | $42K | Sell |
251
-115
| -31% | -$22.1K | ﹤0.01% | 5895 |
|
|
2020
Q4 | $86K | Buy |
366
+228
| +165% | +$31.7K | ﹤0.01% | 5415 |
|
|
2020
Q3 | $14K | Buy |
138
+48
| +53% | +$2.57K | ﹤0.01% | 5832 |
|
|
2020
Q2 | $3K | Sell |
90
-413
| -82% | -$16.4K | ﹤0.01% | 6067 |
|
|
2020
Q1 | $17K | Buy |
503
+369
| +275% | +$21.4K | ﹤0.01% | 5641 |
|
|
2019
Q4 | $6K | Sell |
134
-88
| -40% | -$5.78K | ﹤0.01% | 6017 |
|
|
2019
Q3 | $20K | Hold |
222
| – | – | ﹤0.01% | 5809 |
|
|
2019
Q2 | $30K | Buy |
222
+5
| +2% | +$791 | ﹤0.01% | 5701 |
|
|
2019
Q1 | $59K | Buy |
217
+23
| +12% | +$4.98K | ﹤0.01% | 5282 |
|
|
2018
Q4 | $24K | Buy |
194
+188
| +3,133% | +$51K | ﹤0.01% | 5733 |
|
|
2018
Q3 | $3K | Hold |
6
| – | – | ﹤0.01% | 6201 |
|
|
2018
Q2 | $3K | Sell |
6
-1
| -14% | -$532 | ﹤0.01% | 6156 |
|
|
2018
Q1 | $3K | Hold |
7
| – | – | ﹤0.01% | 6156 |
|
|
2017
Q4 | $5K | Sell |
7
-35
| -83% | -$21.1K | ﹤0.01% | 6062 |
|
|
2017
Q3 | $27K | Buy |
42
+27
| +180% | +$14.1K | ﹤0.01% | 5638 |
|
|
2017
Q2 | $7K | Sell |
15
-45
| -75% | -$27.4K | ﹤0.01% | 5856 |
|
|
2017
Q1 | $45K | Buy |
+60
| New | +$53.8K | ﹤0.01% | 5477 |
|
|
2016
Q4 | – | Sell |
-63
| Closed | -$83K | – | 6489 |
|
|
2016
Q3 | $83K | Sell |
63
-12
| -16% | -$13.5K | ﹤0.01% | 5025 |
|
|
2016
Q2 | $66K | Sell |
75
-80
| -52% | -$106K | ﹤0.01% | 5070 |
|
|
2016
Q1 | $217K | Buy |
155
+8
| +5% | +$11.4K | ﹤0.01% | 4363 |
|
|
2015
Q4 | $271K | Sell |
147
-32
| -18% | -$64K | ﹤0.01% | 4272 |
|
|
2015
Q3 | $350K | Buy |
179
+15
| +9% | +$35.1K | ﹤0.01% | 4169 |
|
|
2015
Q2 | $372K | Sell |
164
-32
| -16% | -$75.1K | ﹤0.01% | 4269 |
|
|
2015
Q1 | $550K | Buy |
+196
| New | +$515K | ﹤0.01% | 3887 |
|
Other funds holding TCON
Wells Fargo's TCON Position: Q2 2024 in Review
Wells Fargo sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2024, closing a stake of 10 shares — an estimated $89 sold.
Wells Fargo first reported a position in TCON in Q1 2015 and held it in 36 quarters. The position peaked at $550K in Q1 2015. 1 fund tracked by Wall St. Rank holds TCON as of Q2 2024.
- Wells Fargo reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Wells Fargo sold 10 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $89.
- Wells Fargo first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2015 and held it in 36 quarters.
- Wells Fargo's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $550K in Q1 2015.
- 1 fund tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.